BMS profits hit by subprime crisis

What's a drugmaker doing, investing in securities at least partly backed by subprime mortgages? Ask Bristol-Myers Squibb, which took a $275 million write-down on so-called "auction rate securities" that had fallen in value to $419 million from $811 million. It also recorded a $142 million loss from a "temporary" plunge in the value of similar securities without subprime backing.

At the time BMS made these investments, the securities had triple-A status with the ratings agencies; they were part of the company's cash-management strategy. Now, says CEO James Cornelius, BMS will trade higher yields for safety, boosting its investment in T-bills.

This footnote to BMS's quarterly results shines a bright light on the subprime monster's many tentacles. Persuaded by the ratings' agencies thumbs-up, lots of savvy investors indulged. How many other seemingly conservative investment portfolios have been touched?

- see the release from BMS
- check out this article in the Financial Times
- read the WSJ Health Blog item

Suggested Articles

Pfizer has scored FDA approval for its Humira biosimilar, but it can't launch the product for several years under a patent settlement.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.